S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10

Kezar Life Sciences (KZR) Stock Forecast, Price & News

+0.25 (+5.01%)
(As of 05/27/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
726,390 shs
Average Volume
832,100 shs
Market Capitalization
$316.58 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive KZR News and Ratings via Email

Sign-up to receive the latest news and ratings for Kezar Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

Kezar Life Sciences logo

About Kezar Life Sciences

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.


Kezar Life Sciences (NASDAQ:KZR) PT Lowered to $14.00
Why Kezar Life Sciences Shares Are Getting Hammered
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
$3.85 per share


Net Income
$-54.63 million
Pretax Margin




Free Float
Market Cap
$316.58 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.26 out of 5 stars

Medical Sector

309th out of 1,424 stocks

Pharmaceutical Preparations Industry

118th out of 681 stocks

Analyst Opinion: 3.5Community Rank: 3.9Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -

Kezar Life Sciences (NASDAQ:KZR) Frequently Asked Questions

Is Kezar Life Sciences a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kezar Life Sciences in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Kezar Life Sciences stock.
View analyst ratings for Kezar Life Sciences
or view top-rated stocks.

Are investors shorting Kezar Life Sciences?

Kezar Life Sciences saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 3,600,000 shares, a decline of 14.7% from the April 30th total of 4,220,000 shares. Based on an average daily trading volume, of 1,020,000 shares, the days-to-cover ratio is presently 3.5 days.
View Kezar Life Sciences' Short Interest

When is Kezar Life Sciences' next earnings date?

Kezar Life Sciences is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Kezar Life Sciences

How were Kezar Life Sciences' earnings last quarter?

Kezar Life Sciences, Inc. (NASDAQ:KZR) posted its quarterly earnings results on Thursday, May, 12th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.02.
View Kezar Life Sciences' earnings history

What price target have analysts set for KZR?

3 equities research analysts have issued 1 year target prices for Kezar Life Sciences' shares. Their forecasts range from $14.00 to $22.00. On average, they expect Kezar Life Sciences' share price to reach $16.67 in the next year. This suggests a possible upside of 218.1% from the stock's current price.
View analysts' price targets for Kezar Life Sciences
or view top-rated stocks among Wall Street analysts.

Who are Kezar Life Sciences' key executives?
Kezar Life Sciences' management team includes the following people:
  • Mr. John Franklin Fowler, Co-Founder, CEO & Director (Age 49, Pay $905.06k)
  • Dr. Christopher J. Kirk Ph.D., Co-Founder, Pres, Chief Scientific Officer & Director (Age 49, Pay $658.81k)
  • Dr. Noreen Roth Henig M.D., Chief Medical Officer (Age 57, Pay $705.53k)
  • Dr. Jack Taunton Ph.D., Co-Founder
  • Mr. Marc L. Belsky, CFO & Sec. (Age 67)
  • Mr. Michael Wolfe, VP of Fin. & Bus. Operations
  • Ms. Gitanjali Jain, VP of Investor Relations & External Affairs
  • Mr. Mark Schiller, Sr. VP of Legal Affairs
  • Dr. Neel K. Anand Ph.D., VP of Medicinal Chemistry & Head of Drug Discovery
  • Ms. Pattie Chiang, VP & Corp. Controller
What other stocks do shareholders of Kezar Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kezar Life Sciences investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Pfizer (PFE), VYNE Therapeutics (vyne), Dynavax Technologies (DVAX), Gilead Sciences (GILD), AbbVie (ABBV), Aldeyra Therapeutics (ALDX) and Exelixis (EXEL).

When did Kezar Life Sciences IPO?

(KZR) raised $70 million in an initial public offering on Thursday, June 21st 2018. The company issued 4,700,000 shares at $14.00-$16.00 per share. Jefferies, Cowen, Wells Fargo Securities and William Blair acted as the underwriters for the IPO.

What is Kezar Life Sciences' stock symbol?

Kezar Life Sciences trades on the NASDAQ under the ticker symbol "KZR."

Who are Kezar Life Sciences' major shareholders?

Kezar Life Sciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Bellevue Group AG (8.23%), BlackRock Inc. (5.11%), State Street Corp (3.95%), Vanguard Group Inc. (3.93%), Victory Capital Management Inc. (3.09%) and Northern Trust Corp (0.77%). Company insiders that own Kezar Life Sciences stock include Equal Talent Investments Ltd, Franklin M Berger and Michael Kauffman.
View institutional ownership trends for Kezar Life Sciences

Which institutional investors are selling Kezar Life Sciences stock?

KZR stock was sold by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, Bellevue Group AG, Invesco Ltd., Prosight Management LP, Renaissance Technologies LLC, EAM Investors LLC, Citigroup Inc., and BNP Paribas Arbitrage SA.
View insider buying and selling activity for Kezar Life Sciences
or view top insider-selling stocks.

Which institutional investors are buying Kezar Life Sciences stock?

KZR stock was bought by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., State Street Corp, Vanguard Group Inc., BlackRock Inc., Goldman Sachs Group Inc., Slow Capital Inc., Ghost Tree Capital LLC, and Simplex Trading LLC. Company insiders that have bought Kezar Life Sciences stock in the last two years include Equal Talent Investments Ltd, and Franklin M Berger.
View insider buying and selling activity for Kezar Life Sciences
or or view top insider-buying stocks.

How do I buy shares of Kezar Life Sciences?

Shares of KZR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kezar Life Sciences' stock price today?

One share of KZR stock can currently be purchased for approximately $5.24.

How much money does Kezar Life Sciences make?

Kezar Life Sciences has a market capitalization of $316.58 million. The company earns $-54.63 million in net income (profit) each year or ($1.04) on an earnings per share basis.

How many employees does Kezar Life Sciences have?

Kezar Life Sciences employs 56 workers across the globe.

What is Kezar Life Sciences' official website?

The official website for Kezar Life Sciences is www.kezarlifesciences.com.

How can I contact Kezar Life Sciences?

Kezar Life Sciences' mailing address is 4000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at (650) 822-5600 or via email at [email protected].

This page was last updated on 5/28/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.